- Home
- / VistaGen Therapeutics
VistaGen Therapeutics
Stock Price
$3
2024-10-29
Market Capitalization
$82.5 M
2024-10-29
Revenue
$1.3 M
FY, 2026
VistaGen Therapeutics Summary
Company Summary
- Overview
- VistaGen Therapeutics is a biopharmaceutical company that develops and commercializes intranasal products. It offers nasal sprays, investigational neuroactive steroids, oral N-methyl-D-aspartate (NMDA) glycine site antagonists, tasteless synthetic pheromones, etc. The company also specializes in mental health support.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://www.vistagen.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jon S. Saxe, Chairman of the Board
Jerry Gin, Director
Ann Cunningham, Chief Commercial Officer and Director
LocationsView all
1 location detected
South San Francisco, CA HQ
United States
343 Allerton Avenue
VistaGen Therapeutics Financials
Summary Financials
- Revenue (FY, 2026)
- $1.3M
- Net income (FY, 2026)
- ($69.7M)
- Cash (FY, 2026)
- $30.8M
- EBIT (FY, 2026)
- ($72.1M)
- Enterprise value
- $53.6M